S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
S&P 500   3,629.65 (-0.16%)
DOW   29,872.47 (-0.58%)
Log in
ARCA:VNRX

VolitionRx Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume187,959 shs
Market Capitalization$171.07 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRx Limited is headquartered in Austin, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone646 650 1351
Employees50

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.10 million
Book Value$0.35 per share

Profitability

Net Income$-16,100,000.00

Miscellaneous

Market Cap$171.07 million
Next Earnings DateN/A
OptionableOptionable
30 days | 90 days | 365 days | Advanced Chart

Receive VNRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VNRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VolitionRx (ARCA:VNRX) Frequently Asked Questions

What stocks does MarketBeat like better than VolitionRx?

Wall Street analysts have given VolitionRx a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VolitionRx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of VolitionRx's key competitors?

Who are VolitionRx's key executives?

VolitionRx's management team includes the following people:
  • Dr. Martin Charles Faulkes, Exec. Chairman (Age 76, Pay $191.31k)
  • Mr. Cameron Reynolds, Founder, CEO, Pres & Director (Age 49, Pay $410.17k)
  • Mr. David Vanston, CFO & Treasurer (Age 52, Pay $209.27k)
  • Dr. Jacob Vincent Micallef, Chief Scientific Officer (Age 64, Pay $191.31k)
  • Dr. Jason Bradley Terrell, Chief Medical Officer & CEO of Volition America, Inc. (Age 40, Pay $328.61k)
  • Mr. Scott Powell, Exec. VP of Investor Relations
  • Ms. Louise Batchelor Day, Chief Marketing & Communications Officer
  • Mr. Thomas Bygott, Sales & Marketing Director
  • Mr. Nathan Dewsbury, Chief Commercial Officer of Volition Veterinary Diagnostics Devel. LLC
  • Dr. Terry Kelly, Chief Scientific Officer of Volition America Inc

What is VolitionRx's stock symbol?

VolitionRx trades on the ARCA under the ticker symbol "VNRX."

How do I buy shares of VolitionRx?

Shares of VNRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is VolitionRx?

VolitionRx has a market capitalization of $0.00 and generates $17.10 million in revenue each year. The company earns $-16,100,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. VolitionRx employs 50 workers across the globe.

What is VolitionRx's official website?

The official website for VolitionRx is www.volition.com.

How can I contact VolitionRx?

The company can be reached via phone at 646 650 1351.

This page was last updated on 11/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.